Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 12/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131483 | 0.91 | GGPS1 (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL6771978 | 0.79 | FDPS (0.51) | FDPSSMPD1LAP3 | |
| Phosphoric Acid SCHEMBL670802 | 0.79 | LAP3 (0.53) | FDPSSMPD1LAP3 | |
| Phosphoric Acid SCHEMBL2806140 | 0.79 | LAP3 (0.53) | FDPSSMPD1LAP3 | |
| Phosphoric Acid SCHEMBL4615576 | 0.77 | LAP3 (0.52) | FDPSSMPD1LAP3 | |
| SCHEMBL6767199 | 0.75 | FDPS (0.50) | FDPSSMPD1GGPS1LAP3 | |
| SCHEMBL28901725 | 0.74 | GGPS1 (0.47) | FDPSSMPD1GGPS1LPAR1LPAR3 | |
| SCHEMBL8858304 | 0.73 | FDPS (0.48) | FDPSSMPD1GGPS1LAP3 | |
| Hydrochloric Acid SCHEMBL9635702 | 0.73 | SPHK1 (0.44) | FDPSSMPD1GGPS1 | |
| Bromide SCHEMBL9716432 | 0.73 | SPHK1 (0.44) | FDPSSMPD1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2021-11-16 | — | — | US | claimed |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | YALE UNIVERSITY (US) | 2020-07-14 | — | — | US | claimed |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | NATIONAL SCIENCE FOUNDATION | 2020-06-11 | — | — | US | claimed |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | MODULATE THERAPEUTICS INC (CA) | 2019-07-11 | — | — | US | claimed |
| EP-2836234-B1 | VEHICLES FOR CONTROLLED DELIVERY OF DIFFERENT PHARMACEUTICAL AGENTS | UNIV YALE (US) | 2019-06-12 | — | — | EP | claimed |
| US-10195144-B2 | Methods of treating inflammatory and autoimmune diseases and disorders | YALE UNIVERSITY (US) | 2019-02-05 | — | — | US | claimed |
| US-20170224617-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | MODULATE THERAPEUTICS INC (CA) | 2017-08-10 | — | — | US | claimed |
| US-9610250-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2017-04-04 | — | — | US | claimed |
| US-9603800-B2 | Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels | YALE UNIVERSITY (US) | 2017-03-28 | — | — | US | claimed |
| US-20150118318-A1 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders | YALE UNIVERSITY (US) | 2015-04-30 | — | — | US | claimed |
| EP-2860255-A1 | Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells | Technische Universität Graz (AT) | 2015-04-15 | — | — | EP | claimed |
| US-20150064265-A1 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents | YALE UNIVERSITY | 2015-03-05 | — | — | US | claimed |
| WO-2024137455-A1 | NANOPARTICULATE FORMULATION | NEWIMMUNE II, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240211771-A1 | SEQUENCE-CONTROLLED POLYMER RANDOM ACCESS MEMORY STORAGE | U.S. DEPARTMENT OF ENERGY | 2024-06-27 | — | — | US | disclosed |
| US-11969396-B2 | IPA-3-loaded liposomes and methods of use thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-11961008-B2 | Sequence-controlled polymer random access memory storage | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2009061003-A2 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-14 | — | — | WO | disclosed |
| EP-1946761-A1 | CARRIER COMPOSITION FOR NUCLEIC ACID TRANSPORT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1920765-A1 | Liposome preparation by single-pass process | Medigene AG (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1915987-A1 | Spray-freeze-drying process for the preparation of pellets comprising percolation drying | MediGene AG (DE) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064265-A1 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | FDPS 2720/4885SMPD1 1303/4885GGPS1 2595/4885 |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | LIPA, ABCF1, ABCG2 | FDPS 2796/4885SMPD1 1136/4885GGPS1 2708/4885 |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | UACA, HLA-DRB1, TNF | FDPS 2545/4885SMPD1 749/4885GGPS1 1607/4885 |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | FDPS 2720/4885SMPD1 1303/4885GGPS1 2595/4885 |
| US-20170224617-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | UACA, HLA-DRB1, TNF | FDPS 2545/4885SMPD1 749/4885GGPS1 1607/4885 |
| US-11969396-B2 | IPA-3-loaded liposomes and methods of use thereof | PAK3, PAK1, PAK6 | FDPS 2740/4885SMPD1 27/4885GGPS1 500/4885 |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | LIPA, CD44, ABCB4 | FDPS 2538/4885SMPD1 738/4885GGPS1 2123/4885 |
| US-20150118318-A1 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders | UACA, HLA-DRB1, TNF | FDPS 2545/4885SMPD1 749/4885GGPS1 1607/4885 |
| US-10195144-B2 | Methods of treating inflammatory and autoimmune diseases and disorders | UACA, HLA-DRB1, LIPA | FDPS 2576/4885SMPD1 737/4885GGPS1 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.